Canada's Cronos Q4 revenue rises 47%, beats estimates

Cronos

26/02/2026 12:42

Overview

Canada cannabis firm's Q4 revenue rose 47%, beating analyst expectations

Adjusted EBITDA for Q4 missed analyst expectations

Company plans strategic acquisition of CanAdelaar to expand in Europe

Outlook

Cronos expects sustainable net revenue and Adjusted EBITDA growth in 2026

Company anticipates closing CanAdelaar acquisition in first half of 2026

Cronos plans to leverage borderless product strategy in Netherlands

Result Drivers

INTERNATIONAL SALES - Higher cannabis flower sales in Israel and other countries drove Q4 revenue growth

GROSS PROFIT INCREASE - Q4 gross profit rose due to higher average sales prices and volumes, particularly in Israel

FOREIGN CURRENCY IMPACT - Net loss in Q4 attributed to foreign currency transaction losses

Company press release: ID:nGNX56GKKQ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$44.50 mln
$38.72 mln (3 Analysts)
Q4 Net Income
-$500,000
Q4 Adjusted EBITDA
Miss
$500,000
$3.28 mln (3 Analysts)
Q4 Gross Profit
$16.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Cronos Group Inc is C$4.50, about 18.4% above its February 25 closing price of C$3.80

The stock recently traded at 38 times the next 12-month earnings vs. a P/E of 45 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)